OncoSil Medical Ltd
OSL
Company Profile
Business description
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil device, a localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company operates in one segment being the device development for new medical treatments. Geographically, it derives maximum revenue from Europe and the rest from Australia, the Middle East, and the United Kingdom.
Contact
7 Eden Park Drive
Level 5, Macquarie Park
SydneyNSW2113
AUST: +61 289359629
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
18
Stocks News & Analysis
stocks
Chip stock selloff deepens in Asia, extends to Europe and US
The week’s tech stock rout continues despite strong earnings from TSMC and ASML.
stocks
Downgrade for ASX listed fund manager as redemptions pile on
Persistent outflows erode earnings outlook.
stocks
Tesla stock is down nearly 20% this year. Is it a buy ahead of earnings?
Following the rollout of its first autonomous Cybercab, here’s what we expect from Tesla’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,940.40 | 100.00 | 1.13% |
| CAC 40 | 7,948.69 | 13.99 | 0.18% |
| DAX 40 | 25,579.91 | 197.29 | 0.78% |
| Dow JONES (US) | 52,177.69 | 556.21 | 1.08% |
| FTSE 100 | 10,829.43 | 10.92 | -0.10% |
| HKSE | 24,186.83 | 124.11 | 0.52% |
| NASDAQ | 26,713.03 | 20.16 | 0.08% |
| Nikkei 225 | 65,324.29 | 898.34 | 1.39% |
| NZX 50 Index | 13,753.73 | 79.07 | -0.57% |
| S&P 500 | 7,744.06 | 25.12 | 0.33% |
| S&P/ASX 200 | 8,806.70 | 87.00 | 1.00% |
| SSE Composite Index | 3,716.28 | 8.81 | 0.24% |